Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.81 USD | +2.72% | -0.22% | -20.54% |
Financials (USD)
Sales 2024 * | 694M | Sales 2025 * | 764M | Capitalization | 1.25B |
---|---|---|---|---|---|
Net income 2024 * | 60M | Net income 2025 * | 91M | EV / Sales 2024 * | 1.92 x |
Net Debt 2024 * | 83.94M | Net cash position 2025 * | 119M | EV / Sales 2025 * | 1.48 x |
P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
13.8
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.78% |
Latest transcript on Pacira BioSciences, Inc.
1 day | +2.72% | ||
1 week | -0.22% | ||
Current month | -8.25% | ||
1 month | -6.49% | ||
3 months | -17.25% | ||
6 months | -4.28% | ||
Current year | -20.54% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Director of Finance/CFO | 63 | 11-10-31 | |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 27 M€ | -4.16% | - | |
0.18% | 45 M€ | +0.73% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 26.81 | +2.72% | 497,169 |
24-04-22 | 26.1 | -0.57% | 375,229 |
24-04-19 | 26.25 | +0.57% | 448,972 |
24-04-18 | 26.1 | -2.50% | 622,151 |
24-04-17 | 26.77 | -0.37% | 415,509 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.54% | 1.25B | |
+27.92% | 672B | |
+27.16% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.34% | 217B | |
+6.23% | 199B | |
-8.88% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- PCRX Stock